Safety, tolerability, and nonglycemic effects of incretin-based therapies

R. Keith Campbell, Michael E. Cobble, Timothy S. Reid, Mansur E. Shomali

Research output: Contribution to journalReview articlepeer-review

Abstract

The overall safety profiles of GLP-1 agonists and DPP-4 inhibitors are favorable, with a low incidence of hypoglycemia. This attribute, along with their weight and cardiovascular benefits, particularly with the GLP-1 agonists, make them appropriate choices in our 3 patient cases. Ongoing safety investigations with GLP-1 agonists and DPP-4 inhibitors will provide further clarity to the complete safety profiles of these agents.

Original languageEnglish (US)
Pages (from-to)S20-S27
JournalJournal of Family Practice
Volume59
Issue number9 SUPPL. 1
StatePublished - Sep 1 2010

ASJC Scopus subject areas

  • Family Practice

Fingerprint Dive into the research topics of 'Safety, tolerability, and nonglycemic effects of incretin-based therapies'. Together they form a unique fingerprint.

Cite this